Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Stock Index Futures Tread Water Ahead of U.S. JOLTs Report, Alphabet Earnings on Tap

December S&P 500 E-Mini futures (ESZ24) are up +0.06%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.08% this morning as market participants geared up for the latest reading on U.S. job openings while also awaiting a deluge of corporate earnings reports from heavyweight names.

Barchart

Gold price hits fresh record high, as bitcoin also rallies – as it happened

Analysts say gold is benefited from safe-haven demand amid persistent geopolitical tensions, expectations of monetary policy easing, and mounting uncertainty surrounding the US presidential election.

The Guardian - UK

As activist Starboard engages constructively, here’s a potent prescription for Pfizer’s future success under Dr. Bourla’s watch

Pfizer is getting back on track—but an even more potent prescription for success could be in the cards for the pharmaceutical giant under.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

What to Expect From Pfizer's Q3 2024 Earnings Report

Pfizer is expected to release its fiscal third-quarter earnings later this month, and analysts project a triple-digit profit growth.

Barchart

Should You Follow Activist Investors Into This High-Yield Dividend Stock?

This dividend stock is now on the radar of activist investors, with Starboard eyeing a possible management shakeup.

Barchart

‘The UK is at the back of the race of turtles’: Sanofi’s boss on the need to develop new medicines

Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare

The Guardian - UK

How To Spot Good Value Stocks In A Sea Of Noise

Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Here are the facts that activist critics of Pfizer CEO Albert Bourla are missing, according to a Yale analysis

'Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff Sonnenfeld and Steven Tian.

Fortune

Stock Market Today: Markets Slip on Hot Inflation Print, Layoff News

Economic data continues to complicate expectations for Federal Reserve rate cuts.

Kiplinger

3 High-Yield Stocks for Growing Dividend Income

Each of these companies boasts a solid track record of paying and raising dividends, with yields exceeding 5%.

Barchart

Is This Overlooked Dividend Stock Yielding Almost 6% a Good Turnaround Play?

Despite its dividend yield of nearly 6%, Pfizer stock has failed to win over investors and is in the red YTD. Can the stock finally stage a turnaround, as activist investor Starboard Value has reportedly taken a stake in the company?

Barchart

2 Covered Call Ideas on Pfizer Stock

Today, we’re looking at two covered call examples on Pfizer stock. The first step to finding our covered call candidates is to use the Stock Scanner with the following parameters:

Barchart

One of science’s greatest achievements: how the rapid development of COVID vaccines prepares us for future pandemics

Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 million deaths from the disease. This makes COVID the seventh-deadliest pandemic in recorded history.

The Conversation

Pfizer stock surges after activist takes $1 billion stake

The drugmaker has shed nearly $180 billion in market cap after struggling to chart a new course as the COVID-19 pandemic waned.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

Activist Starboard Takes $1 Billion Stake In Pfizer, Seeks Former Execs' Support: Reports

Starboard has reached out to former Pfizer CEO Ian Read and ex-finance chief Frank D'Amelio, and both have expressed interest in supporting the activist investor's turnaround efforts, reports said.

The Guardian - UK

I thought I was fine with being bald. But the chance of a cure has stirred up all sorts of feelings

It’s almost 30 years since I lost my hair to alopecia. What if Pfizer’s drug Litfulo could bring it back? asks Guardian columnist Emma Beddington

Fortune

RSV can be deadly—especially for older adults. Why aren’t more of them getting the new vaccine?

About 6,000 to 10,000 people 65 and older die from RSV in the U.S. annually, the CDC says.

Barchart

What You Need to Know Ahead of Walgreens Boots Alliance's Earnings Release

With Walgreens Boots Alliance gearing up to release its fourth-quarter earnings later this month, analysts expect a double-digit earnings dip.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

How to Buy PFE For a 6% Discount, or Achieve a 23% Annual Return

Selling cash secured puts on stocks an investor is happy to take ownership of is a great way to generate some extra income.

Barchart

3 Dividend Stocks Yielding 5% To 11% To Scoop Up Now

These three stocks pay out an attractive yield.

The Independent UK

It's time to roll up sleeves for new COVID, flu shots

Fall means it’s time for just about everybody to get up to date on their flu and COVID-19 vaccines

International Business Times

Free COVID-19 Test Kits To Be Available Again

The new kits were supposed to be available for order on Monday

Latin Times

New Migraine Drugs No Better Than Cheap Painkillers: Big Study

Migraine drugs can represent big money for pharmaceutical firms, as shown when Pfizer acquired Biohaven -- which developed rimegepant -- for more than $10 billion in 2022.

Fortune

Will the XEC COVID subvariant bring a fall wave of infections? What to know about symptoms and spread

The U.S. is coming down from its biggest COVID summer surge yet as a new subvariant emerges—but new vaccines are here, too.

Evening Standard

Covid conspiracy theorist convicted of terrorism after Telegram calls for vaccine violence

Patrick Ruane, 55, from Paddington, west London, weaponised social media app Telegram to encourage attacks

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.